LYNBROOK, N.Y., March 6, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, today announced its financial results for the fourth quarter and full year ended December 31, 2013 and provided a corporate update.
Help employers find you! Check out all the jobs and post your resume.